Switch theme
Sign up to access all valuation multiples
Schott Pharma AG & CO KGaA caters to the pharma, biotech and life science industry by providing containment solutions and delivery systems for injectable drugs. Its segments include; Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of the revenue is generated from Drug Containment Solutions segment which includes products like vials, cartridges and ampoules for safe drug containment. Geographically, the company generates revenue from Europe, Middle East, Africa (EMEA), Asia and South Pacific, North America and South America.
1884
4.7K+
LTM Revenue $1.1B
LTM EBITDA $302M
$4.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Schott Pharma has a last 12-month revenue of $1.1B and a last 12-month EBITDA of $302M.
In the most recent fiscal year, Schott Pharma achieved revenue of $1.1B and an EBITDA of $298M.
Schott Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Schott Pharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.0B | $1.1B | XXX | XXX | XXX |
| Gross Profit | $337M | $360M | XXX | XXX | XXX |
| Gross Margin | 33% | 33% | XXX | XXX | XXX |
| EBITDA | $278M | $298M | XXX | XXX | XXX |
| EBITDA Margin | 27% | 27% | XXX | XXX | XXX |
| Net Profit | $143M | $173M | XXX | XXX | XXX |
| Net Margin | 14% | 16% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 28, 2025, Schott Pharma's stock price is EUR 24 (or $27).
Schott Pharma has current market cap of EUR 3.6B (or $4.1B), and EV of EUR 3.6B (or $4.1B).
See Schott Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.1B | $4.1B | XXX | XXX | XXX | XXX | $1.15 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 28, 2025, Schott Pharma has market cap of $4.1B and EV of $4.1B.
Schott Pharma's trades at 3.7x LTM EV/Revenue multiple, and 13.7x LTM EBITDA.
Analysts estimate Schott Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Schott Pharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $4.1B | XXX | XXX | XXX |
| EV/Revenue | 3.7x | XXX | XXX | XXX |
| EV/EBITDA | 13.7x | XXX | XXX | XXX |
| P/E | 23.7x | XXX | XXX | XXX |
| P/E/Growth | 1.9x | XXX | XXX | XXX |
| EV/FCF | 52.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSchott Pharma's NTM/LTM revenue growth is 9%
Schott Pharma's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $32K for the same period.
Over next 12 months, Schott Pharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Schott Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Schott Pharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 37% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $32K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 8% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 14% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Ansell | XXX | XXX | XXX | XXX | XXX | XXX |
| Polymed | XXX | XXX | XXX | XXX | XXX | XXX |
| Fresenius Medical Care | XXX | XXX | XXX | XXX | XXX | XXX |
| Fresenius | XXX | XXX | XXX | XXX | XXX | XXX |
| Gerresheimer | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Schott Pharma acquired XXX companies to date.
Last acquisition by Schott Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Schott Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Schott Pharma founded? | Schott Pharma was founded in 1884. |
| Where is Schott Pharma headquartered? | Schott Pharma is headquartered in Germany. |
| How many employees does Schott Pharma have? | As of today, Schott Pharma has 4.7K+ employees. |
| Is Schott Pharma publicy listed? | Yes, Schott Pharma is a public company listed on ETR. |
| What is the stock symbol of Schott Pharma? | Schott Pharma trades under 1SXP ticker. |
| When did Schott Pharma go public? | Schott Pharma went public in 2023. |
| Who are competitors of Schott Pharma? | Similar companies to Schott Pharma include e.g. Ansell, Polymed, Fresenius Medical Care, Fresenius. |
| What is the current market cap of Schott Pharma? | Schott Pharma's current market cap is $4.1B |
| What is the current revenue of Schott Pharma? | Schott Pharma's last 12-month revenue is $1.1B. |
| What is the current EBITDA of Schott Pharma? | Schott Pharma's last 12-month EBITDA is $302M. |
| What is the current EV/Revenue multiple of Schott Pharma? | Current revenue multiple of Schott Pharma is 3.7x. |
| What is the current EV/EBITDA multiple of Schott Pharma? | Current EBITDA multiple of Schott Pharma is 13.7x. |
| What is the current revenue growth of Schott Pharma? | Schott Pharma revenue growth between 2023 and 2024 was 7%. |
| Is Schott Pharma profitable? | Yes, Schott Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
